269 related articles for article (PubMed ID: 23085463)
41. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
42. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
43. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
44. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
[TBL] [Abstract][Full Text] [Related]
45. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
46. Drug-mediated and cellular immunotherapy in multiple myeloma.
Ritchie DS; Quach H; Fielding K; Neeson P
Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
[TBL] [Abstract][Full Text] [Related]
47. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG; Schlossman RL; Weller E; Hideshima T; Mitsiades C; Davies F; LeBlanc R; Catley LP; Doss D; Kelly K; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo JJ; Chauhan D; Balinski K; Zeldis J; Anderson KC
Blood; 2002 Nov; 100(9):3063-7. PubMed ID: 12384400
[TBL] [Abstract][Full Text] [Related]
48. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
49. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Busch A; Zeh D; Janzen V; Mügge LO; Wolf D; Fingerhut L; Hahn-Ast C; Maurer O; Brossart P; von Lilienfeld-Toal M
Clin Exp Immunol; 2014 Aug; 177(2):439-53. PubMed ID: 24712857
[TBL] [Abstract][Full Text] [Related]
50. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
51. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
52. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
[TBL] [Abstract][Full Text] [Related]
53. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
Alsina M; Becker PS; Zhong X; Adams A; Hari P; Rowley S; Stadtmauer EA; Vesole DH; Logan B; Weisdorf D; Qazilbash M; Popplewell LL; McClune B; Bensinger W; Riches M; Giralt SA; Pasquini MC;
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1183-9. PubMed ID: 24769014
[TBL] [Abstract][Full Text] [Related]
54. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
55. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
56. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Shimoni A; Zagrivnaja M; Ayuk F; Lioznov M; Schieder H; Renges H; Fehse B; Zabelina T; Nagler A; Zander AR
Blood; 2004 Nov; 104(10):3361-3. PubMed ID: 15292062
[TBL] [Abstract][Full Text] [Related]
57. [Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma].
Yang Y; Zhang WG; He AL; Yang HY; Wang JL; Tian W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):538-42. PubMed ID: 18549624
[TBL] [Abstract][Full Text] [Related]
58. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
59. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
Nguyen-Pham TN; Jung SH; Vo MC; Thanh-Tran HT; Lee YK; Lee HJ; Choi NR; Hoang MD; Kim HJ; Lee JJ
J Immunother; 2015 Oct; 38(8):330-9. PubMed ID: 26325377
[TBL] [Abstract][Full Text] [Related]
60. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
